Schizophrenia is a relatively uncommon disease, affecting about 1% of the world’s population. However, because of its symptoms, schizophrenia can be quite chronic and debilitating. Globally, approximately 1.5 million people will be diagnosed with schizophrenia each year.
Most often, new cases of schizophrenia occur in the teen years of adolescence, reaching a peak of vulnerability between the ages of 16 and 25 years. The full onset of schizophrenia is normally preceded by a prodromal period where the individual experiences odd behaviors such as restlessness, hallucinations and anxiety. During the prodromal period, the behaviors and thoughts generally present gradually, but not yet with their fullest force. It is common for the individual to notice the changes a few months before anyone else visibly recognizes the differences in behavior.
Common symptoms of schizophrenia include hallucinations, delusions and thought disorder, and can include lowered expression of emotions, reduced motivation, difficulty in relationships and cognitive impairment. If left untreated, the symptoms of schizophrenia can expand and present more persistently later in life.
Approximately half of individuals with schizophrenia have co-occurring mental and/or behavioral health disorders.
As per the focus of our ASPIRe program, our personal experiences, and the research advancements being made by our schizophrenia focused Rising Star Awardees, One Mind firmly believes that early interventions can significantly improve the course of schizophrenia.
Through our One Mind Rising Star Awards grant program and other funding support channels, One Mind has supported the following scientists in their important and influential schizophrenia focused research: